Jaime L. Chase

Cooley advised NeuroPace (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, on its $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility.

Cooley advised Bicycle Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of medicines referred to as Bicycle molecules, on its $555.5 million private placement offering. Partners Laura Berezin, Jaime Chase and Claire Keast-Butler led the Cooley team.

Cooley advised IN8Bio on its $40 million initial public offering of 4,000,000 shares of common stock. IN8Bio, whose securities now trade on the Nasdaq Global Market under the symbol INAB, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell therapies. Partners Josh Kaufman, Jaime Chase and Josh Rottner led the Cooley team.

Cooley advised Sprinklr on its $292.6 million initial public offering of 18,287,500 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Sprinklr, whose securities now trade on the New York Stock Exchange under the symbol CXM, is the unified customer experience management platform for modern enterprises. Partners Nicole Brookshire, Josh Kaufman and Jaime Chase led the Cooley team.

Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, on its agreement to sell to Amgen in an all-cash transaction with an equity value of approximately $1.9 billion. Partners Jamie Leigh, Ian Nussbaum and Laura Berezin led the Cooley team advising Five Prime.